All PlansCoverageLow impact
JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology, Pathology·Medical Policy
We identified it
Jun 20, 2026
Summary
New medical policy A.2.04.60 establishes coverage criteria for JAK2, MPL, and CALR genetic testing used to diagnose myeloproliferative neoplasms (blood cancers like polycythemia vera, essential thrombocythemia, and primary myelofibrosis). The policy provides detailed background on when these genetic tests are medically necessary but does not specify billing codes or coverage determinations.
Action Required
Review policy A.2.04.60 to understand coverage criteria for JAK2, MPL, and CALR genetic testing when submitting claims for myeloproliferative neoplasm diagnosis. Ensure documentation supports medical necessity for these specialized genetic tests. Monitor for future updates that may specify billing codes and prior authorization requirements.